期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 22, 期 45, 页码 9880-9897出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v22.i45.9880
关键词
Hepatic steatosis; Fibrosis; Non-invasive assessment; Blood biomarker; Ultrasound
资金
- British Medical Research Council
- Wellcome Trust (London, United Kingdom)
- Sir Halley Stewart Trust (Cambridge, United Kingdom)
- European Union Framework 7
- Medical Research Council [MC_PC_12015, MC_UP_A900_1120] Funding Source: researchfish
- MRC [MC_PC_12015] Funding Source: UKRI
Chronic liver disease is a major cause of morbidity and mortality worldwide and usually develops over many years, as a result of chronic inflammation and scarring, resulting in end-stage liver disease and its complications. The progression of disease is characterised by ongoing inflammation and consequent fibrosis, although hepatic steatosis is increasingly being recognised as an important pathological feature of disease, rather than being simply an innocent bystander. However, the current gold standard method of quantifying and staging liver disease, histological analysis by liver biopsy, has several limitations and can have associated morbidity and even mortality. Therefore, there is a clear need for safe and non-invasive assessment modalities to determine hepatic steatosis, inflammation and fibrosis. This review covers key mechanisms and the importance of fibrosis and steatosis in the progression of liver disease. We address non-invasive imaging and blood biomarker assessments that can be used as an alternative to information gained on liver biopsy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据